Even though Becton, Dickinson and Company (NYSE:BDX) posted strong earnings, investors appeared to be underwhelmed. We have done some analysis and have found some comforting factors beneath the ...

Becton Dickinson gained attention this week with the global launch of its new cell analyzer, integrating advanced spectral and real-time cell imaging technologies. This development coincided with ...

Shares of Becton Dickinson & Co. BDX shed 2.46% to $171.02 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.10% to ...

Franklin Lakes, New Jersey-based Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment ...

In this article, we are going to take a look at where Becton, Dickinson and Company (NYSE:BDX) stands against the other oversold stocks. Due to the uncertainty surrounding the tariff news ...

Goldman Sachs also downgraded Becton Dickinson from Buy to Neutral, with a new price target of $192. Stifel, while maintaining a Buy rating, decreased its price target from $280 to $224.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The latest price target for Becton Dickinson (NYSE:BDX) was reported by Barclays on June 3, 2025. The analyst firm set a price target for $241.00 expecting BDX to rise to within 12 months (a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Becton, Dickinson and Company tumbled 18.1% following the release of its mixed Q2 2025 results on May 1. The company reported revenue of $5.3 billion, up 4.5% year-over-year and slightly below ...